|
Synonyms: Envida® | KN-035 | KN035
envafolimab is an approved drug (China (2021))
Compound class:
Antibody
Comment: Envafolimab (KN035) is a chimeric (human/camelid) anti-PD-L1 nanobody that acts as an immune checkpoint inhibitor, and which is being developed by Alphamab Co [1]. Structurally it is a VH-Fc dimer, and does not contain variable light (VL) domains. It therefore has a reduced molecular size and offers more favourable physico-chemical properties than full-size monoclonal antibodies. X-ray crystal structures show that KN035 binds to the same surface on PD-L1 where the ligand interacts with its cognate receptor PD-1 (programmed death protein 1).
The peptide sequence of envafolimab's heavy chain returned no matches with patented peptide sequences in a Protein: BLAST search in September 2019. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (China (2021)) |
| Approved drug? | Yes. China (2021) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10930 | envafolimab |
| Synonyms |
| Envida® | KN-035 | KN035 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 934 |
| Other databases | |
| GtoPdb PubChem SID | 387065574 |
| Search PubMed clinical trials | envafolimab |
| Search PubMed titles | envafolimab |
| Search PubMed titles/abstracts | envafolimab |
